CHONG KUN DANG PHARMACEUTICAL CORP.

Better Life Through Better Medicine

Copyright ⓒ 2020 Chong Kun Dang Pharmaceutical Corp. All rights reserved.
 ABOUT THE COMPANY

CKD FAST FACTS & FINANCIAL HIGHLIGHTS

CHONG KUN DANG HOLDINGS
Chong Kun Dang Pharmaceutical Corp.
• Development & Sales of pharmaceutical products

Kyongbo Pharmaceutical Co. Ltd.

• Synthetic API & Generic products

Chong Kun Dang Bio Corp.

• API & Intermediates from fermentation
1000
Chong Kun Dang Healthcare Corp.
• Dietary supplements 800

600
CSR ACTIVITY GROUP OTHERS
400
Sowha Children’s Hospital CKD Venture Capital
Kochon Foundation Chong Kun Dang Industry Corp.
200
Kochon School Bellcom / Bell I&S / Bell E&C
0
2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019

Copyright ⓒ 2020 Chong Kun Dang Pharmaceutical Corp. All rights reserved. Source: CKD internal data, Applicable exchange rate: KRW 1,158 2
 ABOUT THE COMPANY

MAJOR ACHIEVEMENTS

Opened new GMP manufacturing Opened Vietnam

facility in Cheonan in 1998 representative office

CKD

KOSPI
CKD-732

1941 1976 2004 2009 2014 2019

Chong Kun Lee Listed on the Launched Camtobell® CKD-732(Beloranib) Launched Duvie® CKD ranked the 1st
founded Goongbon Korea Stock (belotecan) PWS (lobeglitazone) among local
Pharmacy Exchange 8th
New Drug L/O to Zafgen (US) 20th New Drug manufacturers since 2016
developed in Korea developed in Korea (Ref. IMS)

The 1st in Korea to manufacture

chloramphenicol under US FDA approval Established PT CKD-OTTO
and export to Japan Pharmaceuticals,
a JV in Indonesia

Copyright ⓒ 2020 Chong Kun Dang Pharmaceutical Corp. All rights reserved. 3
 ABOUT THE COMPANY

CKD DOMESTIC SALES PERFORMANCE AND COVERAGE

SALES EXCELLENCY SALES BY THERAPEUTIC CLASS COVERAGE BY CHANNEL

1st among local manufacturers in 2019

even without considering the
44% sales mainly from Metabolism and
Cardiovascular area 100% covered by CKD MRs in tertiary
hospitals and hospitals
domestic co-promotion CKD is traditionally strong in
performances Immunosuppressant and growing
its presence in CNS area
2ND top sales in clinics among all
pharmaceutical companies in Korea
570

20% 90% 99%

Others
23%
Endo-metabolic
Unit: Mill USD

Clinic
Y2019 Coverage
10%
Immuno- 1.034 mil. Rate
suppressant USD*
21%
56%
Cardiovascular
12% Internal Medicine
CKD H D J G Anti-infective Family Medicine
14% General Practitioner
CNS
* Source: IMS, Applicable exchange rate: KRW 1,158 * Source: Internal Data (including co–promotion sales) * Source: Internal Data

Copyright ⓒ 2020 Chong Kun Dang Pharmaceutical Corp. All rights reserved.
4
 ABOUT THE COMPANY

CKD ORGANIZATION
Total of around 2,200 employees are working in CKD and over 50% of human resources is dedicated to sales & marketing

LOCATION OF CENTERS

Headquarter
: Seoul

HR, FINANCE RESEARCH PRODUCTION R&D Center

& STRATEGIES & DEVELOPMENT : Yong-in

Manufacturing site
: Cheon-An

Sales Offices
: Multiple sales offices
cover all the regions
MARKETING SALES DEVELOPMENT
& GLOBAL DEV.

• Red dots indicate CKD sales offices

Copyright ⓒ 2020 Chong Kun Dang Pharmaceutical Corp. All rights reserved. 5
 ABOUT THE COMPANY

CKD MANUFACTURING CAPABILITIES

MAIN FACTORY OF CKD KYONGBO PHARM. (API)
CHEON-AN, KOREA ASAN, KOREA
Over 50 products registered in Japanese DMF
Area : 146,296 m2 Established cGMP for US, EU, Japan and China
Employees : 565
Capacity : Audited and approved by :
• Tablet 1,600 mil. Tablets/yr • ANVISA (Brazil)
• Capsule 400 mil. Capsules/yr • PMDA (Japan)
• Liquid Solution 23 mil. bottles/yr • MOH (Germany)
• Others 176 mil. units/yr • MFDS (Korea)
• NMPA (China)

BIO PLANT CKD-OTTO PHARMA

CHEON-AN, KOREA
98 employees for producing bio products
Above the ground of 2,615 m²
Commercial batch started 2Q 2019
LIPPO CIKARANG, INDONESIA
Specialized in oncology drug product.
Technology transfer from Korea to produce sterile
injections and lyophilized powders
Commercial batch started in 2019

Copyright ⓒ 2020 Chong Kun Dang Pharmaceutical Corp. All rights reserved. 6
 ABOUT THE COMPANY

RESEARCH AND DEVELOPMENT

R&D CENTER R&D EXPENDITURE
3 Highly organized departments in the center maximize the
scientific inquiry and support of the development of new drugs Over 12% Of CKD’s total revenue is consistently
used for Research & Development

NEW CHEMICAL ENTITY

 Innovative drug development by targeting platform :
HDAC6 (immune, neuro, cancer)
 Best-in-Class : with targets that have been proven to be
effective

BIOLOGICS
 GMP manufacturing infrastructure for biologics
 Oversea business with bio-similar
 Development of new bio drugs through open
innovation

TECHNOLOGY (INCREMENTALLY MODIFIED DRUG)

 Extending IMD pipeline for market share expansion
 Using platform technology to enter the global market

Copyright ⓒ 2020 Chong Kun Dang Pharmaceutical Corp. All rights reserved. 7
 ABOUT THE COMPANY

MAIN FOCUS AREA

CKD is focusing on the discovery and development of new drugs in therapeutic areas of interest with our collaboration partners
through open innovation

Oncology In-house chemical libraries

CKD is operating in-house new chemical libraries with
selective mechanism of action to develop the
innovative drug globally under strong science and
experiences
Immunology

Pursuing open innovation

In order to achieve external scientific insights and to
strengthen drug discovery capability, CKD is currently
Neuroscience in collaboration with top medical schools around the
world and general hospitals in Korea

YONSEI SNU HARVARD

Copyright ⓒ 2020 Chong Kun Dang Pharmaceutical Corp. All rights reserved. 8
 ABOUT THE COMPANY

R&D PIPELINES
Neuro-degenerative, Oncology and Immunology is the focus of R&D, where multiple pipelines are being developed globally

Biologics Source : Internal data

NCE
* Licensed-in Product MOA MFDS
Discovery Pre-Clinical Phase I Phase II Phase III Launch
Approval

NEURO HD/AD CKD-504 HDAC6 inhibitor Phase 1 (US, Korea)

-DEGENERATIVE CMT CKD-510 HDAC6 inhibitor Phase 1 (Europe)

Solid tumor CKD-702 Bispecific Ab Phase 1 IND (‘20)

Colon cancer CKD-516 Vascular disruptor Phase 1/2a completed (Korea)

ONCOLOGY Multiple myeloma CKD-581 Pan-HDAC inhibitor Phase 1 (Korea)

Multiple myeloma CKD-509 HDAC6 inhibitor
HCC CKD-950* A3AR agonist Phase 2b completed (Global)

RA, IBD CKD-506 HDAC6 inhibitor Phase 2a completed (Europe)

IMMUNOLOGY
Lupus CKD-971* IFNα-kinoid Phase 2b completed (Global)
Approval (Korea, ‘18.11)
Anemia Nesbell® EPO (biosimilar)
(Japan, ‘19.09)
Pain, Uremic Pruritus CKD-943* Κ-opioid R agonist Phase 3 (Global)
AMD CKD-701 Lucentis (biosimilar) Phase 3 (Korea)
OTHERS
Atrial fibrillation Brinavess®* K+ channel blocker NDA in progress

Atrial fibrillation CKD-510 HDAC6 inhibitor Phase 1 (Europe)

Dyslipidemia CKD-508 CEBP inhibitor Phase 1 IND (Europe, ‘20)

Copyright ⓒ 2020 Chong Kun Dang Pharmaceutical Corp. All rights reserved. 9
 ABOUT THE COMPANY

CKD’S GLOBAL ACTIVITIES

2012 Opened Representative Office in Vietnam

2014 Established PT CKD-OTTO, a jointventure in indonesia

● ●
Chong Kun Dang Pharmaceutical
Name Name PT CKD-OTTO Pharmaceuticals
Corp. Representative Office

Business Marketing support Business Production, Sales, Marketing

Portfolio ETC, OTC, Nutrition food Portfolio Anticancer, Immuno-suppresant

Office Ho Chi Minh City, Vietnam Office Jakarta, Indonesia

Copyright ⓒ 2019 Chong Kun Dang Pharmaceutical Corp. All rights reserved. 11
 ABOUT THE COMPANY

CKD’S GLOBAL ACTIVITIES

 Establishment 14 September, 2015

 Business Areas Sales & Marketing,

Manufacturing

 Headquarters Jakarta, Indonesia

 Manufacturing Cikarang, Indonesia

 Main Products Oncology, Immunosuppressant
 Vision To provide patients with
better access to high-quality,
cost-effective medicines in key
therapeutic areas.

Copyright ⓒ 2019 Chong Kun Dang Pharmaceutical Corp. All rights reserved. 12
 ABOUT THE COMPANY

WORLDWIDE PARTNERSHIP (V.1)

COUNTRY PARTNERS PRODUCT NAMES COUNTRY PARTNERS PRODUCT NAMES
Bayer Avelox®, Ciprobay®, Ciprouro® Menarini Neuropacid®
ITALY Italfarmaco CKD Gliatilin®
B.Braun Hospital Solns, Nutriflex®, Lipidem®
GEMANY Cheplapharm Dilatrend®, Anexate®, Xenical®, Cymevene® COSTAIRICA Newport Prinosine®
Riemser Ismo® Can-Fite Namodenoson
UK Atnahs Kytril® ISRAEL Teva Neotigason®, Bezalip®
Roche Tamiflu®, Rivotril®, Valcyte® IRELAND GC Aesthetics Eurosilicone®
Zeller Prefemin®, Cimidona® NETHERLANDS Synthon Vorico®
SWITZERLAND Correvio Brinavess® INDIA Sun Pharma OMPS®
Ferring Minirin®
Cara CKD-943(CR-845) OVERSEAS BUSINESS PARTNERSHIP
Salix Colazal® INDONESIA
S1 Biopharma Lorexys®
Allergan Restasis®, Relestat®
USA MSD Januvia® Family, Vytorin®, Atozet® VIETNAM Ho Chi Minh City Representative Office
Pfizer Xalatan®, Xalacom®, Prevenar13®
Amgen Prolia®
Eli Lilly Olumiant®
Alvogen Mercilon®
Mitsubishi Tanabe Depas®
Ayumi CKD Rimatil®
JAPAN Asahi Kasei Bredinin®, Elcitonin®
ReqMed Penpol®
Eisai Aricept®
Expanscience Imotun®
Vivacy Stylage®
FRANCE Neovacs CKD-971(IFN-alpha kinoid)
OSE Therapeutics Tedopi®

Copyright ⓒ 2020 Chong Kun Dang Pharmaceutical Corp. All rights reserved. 13
 ABOUT THE COMPANY

WORLDWIDE PARTNERSHIP (V.2)

Copyright ⓒ 2020 Chong Kun Dang Pharmaceutical Corp. All rights reserved. 14
 THANK YOU
“We should do more than just making medicines. Our medicines
should always be accessible to those who need them. We must carry
on that mission.”

Founder Chong-Kun Rhee

(1919~1993)

Copyright ⓒ 2020 Chong Kun Dang Pharmaceutical Corp. All rights reserved.